Dr. Pamela Garzone, chief development officer of Anixa Biosciences (NASDAQ:ANIX) will present, “Developing a CAR-T for Ovarian Cancer and Other Solid Tumors,” at the 8th Annual CAR-TCR Summit in Boston August 29 to Sept 1.
The CAR-TCR Summit is the world’s pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types.
Dr. Garzone’s presentation will focus on the opportunities and challenges of CAR-T for solid tumors, routes of administration besides intravenous infusions and details of the ovarian cancer CAR-T therapy clinical trial under the direction of Dr. Robert Wenham at Moffitt Cancer Center and in collaboration with Anixa.
The Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor in patients with recurrent ovarian cancer, will evaluate intraperitoneal and intravenous administration of the CAR-T and the role of lymphodepletion. The study commenced July 2022 and is in progress.
Dr. Garzone also will be hosting a roundtable discussion titled, “Impacting CAR-T Efficacy with Pre-Conditioning Regimens.” Topics covered during this roundtable will include a discussion on differences between lymphodepletion regimens and outcomes for liquid and solid tumors, impact of lymphodepletion intensity on CAR-T cell therapy, and how to achieve optimal balance between efficacy and safety.
